and clinical advice. The results of No RCTs INNOVATE conducted and IA-05 EUP solely in the are UK NHS were generalisable identified. to the UK NHS. Omalizumab Treatment reduces effect exacerbation trial as reported in INNOVATE for adults and adolescents and IA-05 EUP in children. Patients on The RCTs omalizumab evaluating
and clinical advice. Treatment effect The results of INNOVATE and IA-05 EUP are generalisable to the UK NHS. Omalizumab reduces exacerbation as reported in INNOVATE for adults and adolescents and IA-05 EUP in children. No RCTs conducted solely in the UK NHS were identified. Patients on omalizumab The RCTs evaluating trial
1-s2.0-S1098301514019330-mmc1.docx